Molecular biomarkers
T. Aoki (Toronto, Canada)
News on frontline advanced stage
P. Borchmann (Cologne, Germany)
News on frontline advanced stage
S.M. Smith (Chicago, USA)
Primary refractory/early relapse: a world with different opportunities
P. Armand (Boston, USA) - NOT AUTHORIZED
Novel agents in relapse/refractory patients
R. Advani (Stanford, USA) - NOT AUTHORIZED
AFM13 combined with cord blood-derived NK cell
S. Tiberti (Houston, USA)
SESSION II - PTCL/CTCL

The potential frontline therapies in PTCL
B. Pro (New York, USA)
New targeted agents in PTCL
S.P. Iyer (Houston, USA)
A multidisciplinary approach to the management of CTCL
M. Bagot (Paris, France) - NOT AUTHORIZED
SESSION III - DLBCL (Excluded CAR-T)

The use of molecular profiling for patient selection
D.W. Scott (Vancouver, Canada)
Frontline treatments in DLBCL: the actual scenario and the ongoing trials speculations and potential future vision
G.S. Nowakowski (Rochester, USA)
Is it time to explore the concept of R-CHOP?
J.R. Westin (Houston, USA)
New algorithm for relapsed/refractory patients: is there a role and if so which one for each actor in this orchestra?
S.M. Ansell (Rochester, USA)
Bispecific and beyond
C. Thieblemont (Paris, France)
SESSION IV - FOLLICULAR LYMPHOMA

The new attack on the front line after the Relevance study: competitors and pretenders
L. Falchi (New York, USA)
DEBATE: Pro CAR-T
J.S. Abramson (Cambridge, USA)
DEBATE: Pro bispecifics
M. Hutchings (Copenhagen, Denmark)
The scaling dynamics of chemo-free regimens to the second line
C. Thieblemont (Paris, France)
Novel agents (bispecific, trispecifics, ADCs, BTKi, BCL-2i, and others)
B.D. Cheson (Washington, USA)
SESSION V - LECTURES

BTK degraders update
A.V. Danilov (Duarte, USA)
Shadows and lights and..... the therapeutic future of WM
S.P. Treon (Boston, USA)
SESSION VI - CAR-T Cells

It is time for definitive assessments: how many DLBCL and FL can we cure with CAR-T cells?
S.S. Neelapu (Houston, USA)
Risk of second tumor and T-cell lymphoma after CAR-T cell therapy
S.J. Schuster (Philadelphia, USA)
Allogeneic CAR-T cell: is there a strategy moving forward?
S.S. Neelapu (Houston, USA)
Is the imperfect collaboration between the referral center and the CAR-T center a global risk? How to solve the problem and what are the risks for patients?
J.S. Abramson (Cambridge, USA)
SESSION VII - MANTELL CELL LYMPHOMA

The Copernican revolution on the basis of the TRIANGLE study
M. Dreyling (Munich, Germany)
ENRICH, SHINE and ECHO and beyond BTKi in the FL-treatment of elderly patients
G. Hess (Mainz, Germany)
The role of CAR-T: current and future vision
M. Wang (Houston, USA)
The role of bispecifics
T.J. Phillips (Duarte, USA)
Actual and new strategies for relapsed/refractory patients
M. Williams (Charlottesville, USA)
Privacy Policy | Cookie Policy